2,271 reports of this reaction
2.3% of all RIOCIGUAT reports
#9 most reported adverse reaction
HOSPITALISATION is the #9 most commonly reported adverse reaction for RIOCIGUAT, manufactured by Bayer HealthCare Pharmaceuticals Inc.. There are 2,271 FDA adverse event reports linking RIOCIGUAT to HOSPITALISATION. This represents approximately 2.3% of all 100,865 adverse event reports for this drug.
RIOCIGUAT has an overall safety score of 85 out of 100. Patients taking RIOCIGUAT who experience hospitalisation should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HOSPITALISATION is a less commonly reported adverse event for RIOCIGUAT, but still significant enough to appear in the safety profile.
In addition to hospitalisation, the following adverse reactions have been reported for RIOCIGUAT:
The following drugs have also been linked to hospitalisation in FDA adverse event reports:
HOSPITALISATION has been reported as an adverse event in 2,271 FDA reports for RIOCIGUAT. This does not prove causation, but indicates an association observed in post-market surveillance data.
HOSPITALISATION accounts for approximately 2.3% of all adverse event reports for RIOCIGUAT, making it a notable side effect.
If you experience hospitalisation while taking RIOCIGUAT, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.